Olimel N12e (Valine, Alanine, Arginine, Histidine, Isoleucine, Leucine, Methionine, Phenylalanine, Proline, Serin)

The blend supplies essential and conditionally essential amino acids that are directly taken up by cells and incorporated into new proteins. This replenishes intracellular amino‑acid pools, supports the mTOR pathway, improves nitrogen balance and promotes tissue repair.

The prescribed dose of Olimel N12e is determined by the treating physician based on the patient’s weight, clinical condition, and laboratory parameters. The prescriber sets the infusion volume and rate according to established nutritional guidelines.

Safety data for intravenous amino acid mixtures in pregnancy and lactation are limited. Use is generally reserved for situations where the benefit to the mother outweighs potential risks to the fetus or infant, and only under close medical supervision.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Olimel N12e contains a broad spectrum of ten amino acids, offering a balanced profile for protein synthesis. Compared with single‑amino‑acid solutions, it provides more comprehensive nutritional support, while its sterile powder form allows flexible reconstitution and dosing.

Store the powder at ambient temperature, below 25 °C, in the original sealed container. Protect it from moisture, direct sunlight and extreme temperature fluctuations. Reconstitute with the recommended diluent using aseptic technique immediately before administration.

Olimel N12e is reconstituted with a suitable sterile diluent and administered intravenously over a controlled period, usually as part of a total parenteral nutrition regimen or as a stand‑alone amino‑acid infusion, following aseptic preparation guidelines.

Serious risks include hyperammonemia, severe allergic reactions such as anaphylaxis, electrolyte disturbances and metabolic acidosis. Patients should be monitored closely for these events, especially during the initial infusion period.

Patients with known hypersensitivity to any component of the formulation, uncontrolled hyperkalemia, severe hepatic failure with high ammonia levels, or those for whom a balanced amino‑acid supply is contraindicated should not receive Olimel N12e.